(Q36899104)

17 August 2017

1 reference

title

Dendritic cell vaccination (English)

1 reference

17 August 2017

1 reference

Owen Proudfoot

1

1 reference

17 August 2017

Dodie Pouniotis

2

1 reference

17 August 2017

Kuo-Ching Sheng

3

1 reference

17 August 2017

Bruce E Loveland

4

1 reference

17 August 2017

Geoffrey A Pietersz

5

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Expert Review of Vaccines

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

617-633

1 reference

Development trends for monoclonal antibody cancer therapeutics.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Design of peptide-based vaccines for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells: activation and maturation--applications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells prime natural killer cells by trans-presenting interleukin 15

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Receptor-mediated delivery of antigens to dendritic cells: anticancer applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

RNA transfer and its use in dendritic cell-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Some interfaces of dendritic cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells: limited potential in immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Cellular immunotherapy with dendritic cells in cancer: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Immunophenotypic and functional characterization of cord blood dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Efficient transduction and long-term retroviral expression of the melanoma-associated tumor antigen tyrosinase in CD34(+) cord blood-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Melanoma vaccines--they should work.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Single step enrichment of blood dendritic cells by positive immunoselection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

Dendritic Cell-Based Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.4.617

21 January 2018

Identifiers

DOI

10.1586/14760584.6.4.617

1 reference

17 August 2017

1 reference